HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $75.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 2.11% from the company’s current price.

SRPT has been the topic of several other reports. Royal Bank of Canada cut their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Scotiabank began coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They issued a “sector perform” rating and a $105.00 target price on the stock. Piper Sandler cut their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $167.41.

Sarepta Therapeutics Stock Down 8.2 %

NASDAQ SRPT opened at $73.45 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $7.13 billion, a PE ratio of 58.76 and a beta of 0.79. Sarepta Therapeutics has a 1 year low of $73.06 and a 1 year high of $173.25. The business’s 50-day moving average is $108.20 and its 200 day moving average is $118.54.

Insider Activity at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SRPT. Wealth Enhancement Advisory Services LLC grew its position in Sarepta Therapeutics by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company’s stock worth $571,000 after purchasing an additional 218 shares during the period. GF Fund Management CO. LTD. bought a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Sarepta Therapeutics by 11.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock worth $36,392,000 after purchasing an additional 31,098 shares during the period. Woodline Partners LP bought a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $5,713,000. Finally, Vestal Point Capital LP bought a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $30,398,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.